| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000020271 |
| Receipt No. | R000023402 |
| Scientific Title | Safety evaluation of the consumption of plant-derived processed product in healthy adults: a double-blind, randomized controlled trial with parallel group design. |
| Date of disclosure of the study information | 2016/01/20 |
| Last modified on | 2019/08/26 (Ver. 10) |
| Basic information | ||
| Public title | Safety evaluation of the consumption of plant-derived processed product in healthy adults: a double-blind, randomized controlled trial with parallel group design. | |
| Acronym | Safety evaluation of plant-derived processed product | |
| Scientific Title | Safety evaluation of the consumption of plant-derived processed product in healthy adults: a double-blind, randomized controlled trial with parallel group design. | |
| Scientific Title:Acronym | Safety evaluation of plant-derived processed product | |
| Region |
|
|
| Condition | |||
| Condition | Healthy subjects | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the safety of excessive
consumption of a plant-derived processed product |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | frequency of adverse events at 4 weeks after intervention. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Control food(product code,C-002), administration period = 4 weeks, dosage = 30g/day | |
| Interventions/Control_2 | Test food(product code,A-002), administration period = 4 weeks, dosage = 30g/day | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | -BMI>=22.0 and<30.0 kg/m2
-BMI>=20 and<65 years old -Person who provides inforrned consent by a document |
|||
| Key exclusion criteria | 1) individual with liver, kidney and heart disease, or disorder of respiration, endocrine, metabolism, nervous system, consciousness, or diabetes, or other diseases, 2) individual given surgery within 2 months before the trial, 3) medicine user for hyperglycaemia, lipidemia, or hypertension, 4) individual intakes supplements or the food for specific use of health authorized the government, 5) individual experienced unpleasant feeling during blood drawing, 6) individual donated 200 mL or more blood within 1 month before the trial, 7) individual changed his/her weight 2 kg or more within 1 month before the trial, 8) shiftworker, 9) individual plans bussiness trip for 10 consecutive days or more, 10) individual had allergy against any constituents in the test diet, 11) individual can not conform to alcohol limitation, 12) individual can not conform to record of daily life in a format, 13) individual can not conform to record of daily diet for 9 days (3 days x 3 times), 14) individual cannot allow operator to consult his/her data of the past health check, 15) individual have already participated other clinical trial and will participate, 16) individual cannot accept content of this trial, 17) pregnant women or breast-feeding women, 18) individual who was judged ineligibles by clinician in this trial | |||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kao Corporation | ||||||
| Division name | Health Care Food Research Labs. | ||||||
| Zip code | 131-8501 | ||||||
| Address | 2-1-3 Bunka Sumida-ku Tokyo | ||||||
| TEL | 0356307456 | ||||||
| saito.shinichirou@kao.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | New Drug Research Center, Inc. | ||||||
| Division name | Clinical Research Dept. | ||||||
| Zip code | 061-1405 | ||||||
| Address | 452-1 Toiso, Eniwa-shi, Hokkaido | ||||||
| TEL | 0123-34-0412 | ||||||
| Homepage URL | |||||||
| s-tomita@ndrcenter.co.jp | |||||||
| Sponsor | |
| Institute | New Drug Research Center, Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kao Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The Ethics Review Board of Miyawaki Orthopedic Hospital |
| Address | 3-1-6 Ariake-cho, Eniwa city, Hokkaido |
| Tel | 0123-33-4026 |
| d-kameda@mediffom.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | Unpublished due to the protocol including the intellectual property rights |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | works in progress | ||||||
| Number of participants that the trial has enrolled | 30 | ||||||
| Results | The results suggest that the excessive consumption of test food is safe in healthy subjects. |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Healthy |
||||||
| Participant flow | 30 participants completed and 30 subjects were incorporated into the analyses |
||||||
| Adverse events | No adverse effect related to the test diets reported |
||||||
| Outcome measures | Safety |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023402 |